Looks like the runup to phase 3 results has just begun...GL
"JPMorgan Chase & Co. increased its position in Axsome Therapeutics Inc (NASDAQ:AXSM) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,459,117 shares of the company’s stock after buying an additional 23,229 shares during the period. JPMorgan Chase & Co. owned 6.18% of Axsome Therapeutics worth $8,026,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new stake in shares of Axsome Therapeutics in the second quarter worth about $188,000. Goldman Sachs Group Inc. raised its position in Axsome Therapeutics by 118.7% during the second quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock valued at $372,000 after purchasing an additional 36,698 shares during the period. Finally, Sphera Funds Management LTD. raised its position in Axsome Therapeutics by 24.9% during the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after purchasing an additional 100,000 shares during the period. Institutional investors own 23.62% of the company’s stock." |
